Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cempra Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Formed around a library of macrolide analogs licensed from Optimer Pharmaceuticals, Cempra Pharmaceuticals Inc.’s original intent was to build an improved version of Ketek, the ketolide antibiotic telithromycin that caused liver toxicity problems after its 2004 US launch. Cempra says its lead candidate CEM-101 is two-to-four times more potent than telithromycin. In addition to an oral form, Cempra is also developing an intravenous version that could be used to treat serious infections in the hospital.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts